Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 6/2016

01-06-2016 | Vascular Biology (J. Hamilton, Section Editor)

Sphingosine-1-Phosphate Signaling in Endothelial Disorders

Author: Teresa Sanchez

Published in: Current Atherosclerosis Reports | Issue 6/2016

Login to get access

Abstract

Numerous preclinical studies indicate that sustained endothelial activation significantly contributes to tissue edema, perpetuates the inflammatory response, and exacerbates tissue injury ultimately resulting in organ failure. However, no specific therapies aimed at restoring endothelial function are available as yet. Sphingosine-1-phosphate (S1P) is emerging as a potent modulator of endothelial function and endothelial responses to injury. Recent studies indicate that S1PR are attractive targets to treat not only disorders of the arterial endothelium but also microvascular dysfunction caused by ischemic or inflammatory injury. In this article, we will review the current knowledge of the role of S1P and its receptors in endothelial function in health and disease, and we will discuss the therapeutic potential of targeting S1PR not only for disorders of the arterial endothelium but also the microvasculature. The therapeutic targeting of S1PR in the endothelium could help to bridge the gap between biomedical research in vascular biology and clinical practice.
Literature
1.
Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527–61.PubMed
2.
Ye X, Ding J, Zhou X, Chen G, Liu SF. Divergent roles of endothelial nf-kappab in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med. 2008;205:1303–15.CrossRefPubMedPubMedCentral
3.
Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765–77.CrossRefPubMed
4.
5.
6.
Schwab S, Spranger M, Schwarz S, Hacke W. Barbiturate coma in severe hemispheric stroke: useful or obsolete? Neurology. 1997;48:1608–13.CrossRefPubMed
7.
Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem (Tokyo). 1997;121:969–73.CrossRef
8.
Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295–8.CrossRefPubMed
9.
Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;352(Pt 3):809–15.CrossRefPubMedPubMedCentral
10.••
Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by hdl-associated apolipoprotein m. Proc Natl Acad Sci U S A. 2011;108:9613–8. This study shows that Apo M is the carrier of S1P in HDL and contributes to their vasoprotective effects. CrossRefPubMedPubMedCentral
11.
Yatomi Y, Ruan F, Hakomori S, Igarashi Y. Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood. 1995;86:193–202.PubMed
12.
Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102:669–76.CrossRefPubMedPubMedCentral
13.
Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, et al. Sphingosine-1-phosphate as a ligand for the g protein-coupled receptor edg-1. Science. 1998;279:1552–5.CrossRefPubMed
14.
Sato K, Ui M, Okajima F. Differential roles of edg-1 and edg-5, sphingosine 1-phosphate receptors, in the signaling pathways in c6 glioma cells. Brain Res Mol Brain Res. 2000;85:151–60.CrossRefPubMed
15.
Kon J, Sato K, Watanabe T, Tomura H, Kuwabara A, Kimura T, et al. Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cdna-transfected Chinese hamster ovary cells. J Biol Chem. 1999;274:23940–7.CrossRefPubMed
16.
Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25:11113–21.CrossRefPubMedPubMedCentral
17.
Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the g protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000;106:951–61.CrossRefPubMedPubMedCentral
18.
Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, et al. The sphingosine-1-phosphate receptors s1p1, s1p2, and s1p3 function coordinately during embryonic angiogenesis. J Biol Chem. 2004;279:29367–73.CrossRefPubMed
19.
Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator fty720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453–7.CrossRefPubMed
20.
Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346–9.CrossRefPubMed
21.
Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on s1p receptor 1. Nature. 2004;427:355–60.CrossRefPubMed
22.
Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through s1p lyase inhibition and disruption of s1p gradients. Science. 2005;309:1735–9.CrossRefPubMed
23.
LaMontagne K, Littlewood-Evans A, Schnell C, O’Reilly T, Wyder L, Sanchez T, et al. Antagonism of sphingosine-1-phosphate receptors by fty720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006;66:221–31.CrossRefPubMed
24.
Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282:9082–9.CrossRefPubMed
25.
Windh RT, Lee MJ, Hla T, An S, Barr AJ, Manning DR. Differential coupling of the sphingosine 1-phosphate receptors edg-1, edg-3, and h218/edg-5 to the g(i), g(q), and g(12) families of heterotrimeric g proteins. J Biol Chem. 1999;274:27351–8.CrossRefPubMed
26.
Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301–12.CrossRefPubMed
27.
Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest. 2007;117:2506–16.CrossRefPubMedPubMedCentral
28.••
Kim GS, Yang L, Zhang G, Zhao H, Selim M, McCullough LD, et al. Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nat Commun. 2015;6:7893. This study showed the critical role of S1PR2 in the disruption of cerebrovascular integrity, the development of hemorrhagic transformation and the activation of matrix metalloproteinase-9 in the brain endothelium upon ischemia-reperfusion injury. CrossRefPubMedPubMedCentral
29.
Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, et al. Sphingosine 1-phosphate activates akt, nitric oxide production, and chemotaxis through a gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276:19672–7.CrossRefPubMed
30.
Paik JH, Chae S, Lee MJ, Thangada S, Hla T. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of edg-1 and edg-3 receptors and rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem. 2001;276:11830–7.CrossRefPubMed
31.
Shikata Y, Birukov KG, Birukova AA, Verin A, Garcia JG. Involvement of site-specific fak phosphorylation in sphingosine-1 phosphate- and thrombin-induced focal adhesion remodeling: role of src and git. FASEB J. 2003;17:2240–9.CrossRefPubMed
32.
Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108:689–701.CrossRefPubMedPubMedCentral
33.
Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, Zhan X, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem. 2004;279:24692–700.CrossRefPubMed
34.
Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of rac and cell motility by the g12/13-rho and gi pathways integrated downstream of a single g protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003;23:1534–45.CrossRefPubMedPubMedCentral
35.
Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (s1p) receptors, s1p(2)/lp(b2)/edg-5 and s1p(3)/lp(b3)/edg-3. J Biol Chem. 2002;277:25152–9.CrossRefPubMed
36.
Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, Wu H, et al. Pten as an effector in the signaling of antimigratory g protein-coupled receptor. Proc Natl Acad Sci U S A. 2005;102:4312–7.CrossRefPubMedPubMedCentral
37.
Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (s1p2r) and its downstream effectors rock and pten. Arterioscler Thromb Vasc Biol. 2007;27:1312–8.CrossRefPubMed
38.
Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, et al. Role of scavenger receptor class b type i and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem. 2006;281:37457–67.CrossRefPubMed
39.
Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, Whetzel A, et al. Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol. 2005;25:976–81.CrossRefPubMed
40.
Matsushita K, Morrell CN, Lowenstein CJ. Sphingosine 1-phosphate activates weibel-palade body exocytosis. Proc Natl Acad Sci U S A. 2004;101:11483–7.CrossRefPubMedPubMedCentral
41.
Nussbaum C, Bannenberg S, Keul P, Graler MH, Goncalves-de-Albuquerque CF, Korhonen H, et al. Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial p-selectin. Nat Commun. 2015;6:6416.CrossRefPubMedPubMedCentral
42.••
Zhang G, Yang L, Kim GS, Ryan K, Lu S, O’Donnell RK, et al. Critical role of sphingosine-1-phosphate receptor 2 (s1pr2) in acute vascular inflammation. Blood. 2013;122:443–55. This study demonstrated the role of S1PR2 in the induction of endothelial permeability and inflammation via activation of the NF-κB and the stress activated protein kinase p38 pathways. CrossRefPubMedPubMedCentral
43.
Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276:31780–5.CrossRefPubMed
44.
Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol. 2003;23:1283–8.CrossRefPubMed
45.
Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, et al. High-density lipoprotein binding to scavenger receptor-bi activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–7.CrossRefPubMed
46.
Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem. 2008;283:25074–81.CrossRefPubMedPubMedCentral
47.
Wilkerson BA, Grass GD, Wing SB, Argraves WS, Argraves KM. Sphingosine 1-phosphate (s1p) carrier-dependent regulation of endothelial barrier: High density lipoprotein (hdl)-s1p prolongs endothelial barrier enhancement as compared with albumin-s1p via effects on levels, trafficking, and signaling of s1p1. J Biol Chem. 2012;287:44645–53.CrossRefPubMedPubMedCentral
48.••
Galvani S, Sanson M, Blaho VA, Swendeman SL, Conger H, Dahlback B, et al. Hdl-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor s1p1 to limit vascular inflammation. Sci Signal. 2015;8:ra79. This paper showed that HDL-bound S1P acts as a β-arrestin biased ligand leading to inhibition of endothelial inflammation. It was also shown that endothelial S1PR1 is anti-inflammatory in vivo and prevents the development of atherosclerosis in areas of laminar flow. CrossRefPubMedPubMedCentral
49.
Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, Morris MA, Ley K, et al. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic nod mice through activation of the s1p1 receptor. Circ Res. 2006;99:731–9.CrossRefPubMed
50.
Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res. 2008.
51.
Zhao Y, Gorshkova IA, Berdyshev E, He D, Fu P, Ma W, et al. Protection of lps-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am J Respir Cell Mol Biol. 2011.
52.
Feistritzer C, Riewald M. Endothelial barrier protection by activated protein c through par1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105:3178–84.CrossRefPubMed
53.
Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. Activated protein c mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005;280:17286–93.CrossRefPubMed
54.
Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: role of mop-r and s1p3 transactivation. Am J Respir Cell Mol Biol. 2007;37:222–31.CrossRefPubMed
55.
Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE, et al. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female cns autoimmunity susceptibility. J Clin Invest. 2014;124:2571–84.CrossRefPubMedPubMedCentral
56.
Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A. 1998;95:14196–201.CrossRefPubMedPubMedCentral
57.
Takeya H, Gabazza EC, Aoki S, Ueno H, Suzuki K. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood. 2003;102:1693–700.CrossRefPubMed
58.
Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of hdl. Circ Res. 2004;95:764–72.CrossRefPubMed
59.
Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201–11.CrossRefPubMed
60.
Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, et al. Fty720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007;115:501–8.CrossRefPubMed
61.
Keul P, Tolle M, Lucke S, von Wnuck LK, Heusch G, Schuchardt M, et al. The sphingosine-1-phosphate analogue fty720 reduces atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607–13.CrossRefPubMed
62.
Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, Preusch M, et al. Sphingosine-1-phosphate analogue fty720 causes lymphocyte redistribution and hypercholesterolemia in apoe-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:2392–9.CrossRefPubMed
63.
Poti F, Gualtieri F, Sacchi S, Weissen-Plenz G, Varga G, Brodde M, et al. Krp-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in ldl-r−/− mice. Arterioscler Thromb Vasc Biol. 2013;33:1505–12.CrossRefPubMed
64.
Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:81–5.CrossRefPubMedPubMedCentral
65.
Keul P, Lucke S, von Wnuck LK, Bode C, Graler M, Heusch G, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res. 2011;108:314–23.CrossRefPubMed
66.
Poti F, Ceglarek U, Burkhardt R, Simoni M, Nofer JR. Ski-ii - a sphingosine kinase 1 inhibitor—exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (ldl-r(−/−)) mice on high cholesterol diet. Atherosclerosis. 2015;240:212–5.CrossRefPubMed
67.
Poti F, Bot M, Costa S, Bergonzini V, Maines L, Varga G, et al. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (ldl-r(−/−)) mice. Thromb Haemost. 2012;107:552–61.CrossRefPubMed
68.
Bot M, Van Veldhoven PP, de Jager SC, Johnson J, Nijstad N, Van Santbrink PJ, et al. Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in ldl-receptor deficient mice. PLoS One. 2013;8, e63360.CrossRefPubMedPubMedCentral
69.
Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, et al. Phosphorylation and action of the immunomodulator fty720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem. 2003;278:47281–90.CrossRefPubMed
70.
Jung B, Obinata H, Galvani S, Mendelson K, Ding BS, Skoura A, et al. Flow-regulated endothelial s1p receptor-1 signaling sustains vascular development. Dev Cell. 2012;23:600–10.CrossRefPubMedPubMedCentral
71.
Michaud J, Im DS, Hla T. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol. 2010;184:1475–83.CrossRefPubMedPubMedCentral
72.
Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral s1p1 antagonist in vivo. Nat Chem Biol. 2006;2:434–41.CrossRefPubMed
73.
Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the s1p3 lysophospholipid receptor. Circulation. 2006;114:1403–9.CrossRefPubMed
74.
Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck LK, Baba HA, et al. Hdl induces no-dependent vasorelaxation via the lysophospholipid receptor s1p3. J Clin Invest. 2004;113:569–81.CrossRefPubMedPubMedCentral
75.
Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J. 2003;146:62–8.CrossRefPubMed
76.
Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, et al. Sphingosine 1-phosphate levels in plasma and hdl are altered in coronary artery disease. Basic Res Cardiol. 2010;105:821–32.CrossRefPubMed
77.
Argraves KM, Sethi AA, Gazzolo PJ, Wilkerson BA, Remaley AT, Tybjaerg-Hansen A, et al. S1p, dihydro-s1p and c24:1-ceramide levels in the hdl-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011;10:70.CrossRefPubMedPubMedCentral
78.
Knapp M, Baranowski M, Czarnowski D, Lisowska A, Zabielski P, Gorski J, et al. Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit. 2009;15:CR490–3.PubMed
79.
Sugiura T, Dohi Y, Yamashita S, Ohte N, Ito S, Iwaki S, et al. Analytical evaluation of plasma serotonin and sphingosine 1-phosphate and their clinical assessment in early atherosclerosis. Coron Artery Dis. 2012;23:234–8.CrossRefPubMed
80.••
Sattler K, Lehmann I, Graler M, Brocker-Preuss M, Erbel R, Heusch G, et al. Hdl-bound sphingosine 1-phosphate (s1p) predicts the severity of coronary artery atherosclerosis. Cell Physiol Biochem. 2014;34:172–84. This paper showed that the content of S1P in HDL from CAD patients negatively correlated with the severity of the disease and low HDL-bound S1P predicted the severity of CAD.CrossRefPubMed
81.••
Sattler K, Graler M, Keul P, Weske S, Reimann CM, Jindrova H, et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015;66:1470–85. This study showed that, in patients with CAD, the reduced S1P content in HDL contributes to HDL dysfunction which could be corrected by S1P loading.CrossRefPubMed
82.
Saver JL. Improving reperfusion therapy for acute ischaemic stroke. J Thromb Haemost. 2011;9 Suppl 1:333–43.CrossRefPubMed
83.
Molina CA, Alvarez-Sabin J. Recanalization and reperfusion therapies for acute ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 1:162–7.CrossRefPubMed
84.
Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab. 1996;16:1373–8.CrossRefPubMed
85.
Ames 3rd A, Wright RL, Kowada M, Thurston JM, Majno G. Cerebral ischemia. Ii. The no-reflow phenomenon. Am J Pathol. 1968;52:437–53.PubMedPubMedCentral
86.
del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23:879–94.CrossRefPubMed
87.
Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel MA, Kahles T, Neumann-Haefelin T, et al. The immunomodulatory sphingosine 1-phosphate analog fty720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009;389:251–6.CrossRefPubMed
88.
Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Activation of sphingosine 1-phosphate receptor-1 by fty720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41:368–74.CrossRefPubMedPubMedCentral
89.
Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011.
90.
Liesz A, Sun L, Zhou W, Schwarting S, Mracsko E, Zorn M, et al. Fty720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS One. 2011;6, e21312.CrossRefPubMedPubMedCentral
91.
Campos F, Qin T, Castillo J, Seo JH, Arai K, Lo EH, et al. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke. 2013;44:505–11.CrossRefPubMedPubMedCentral
92.
Kraft P, Gob E, Schuhmann MK, Gobel K, Deppermann C, Thielmann I, et al. Fty720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013;44:3202–10.CrossRefPubMed
93.
Cai A, Schlunk F, Bohmann F, Kashefiolasl S, Brunkhorst R, Foerch C, et al. Coadministration of fty720 and rt-pa in an experimental model of large hemispheric stroke-no influence on functional outcome and blood–brain barrier disruption. Exp Transl Stroke Med. 2013;5:11.CrossRefPubMedPubMedCentral
94.
Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 2014;111:18315–20.CrossRefPubMedPubMedCentral
95.
Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, et al. Combination of an immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015.
96.
Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. Fty720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (s1p1) modulation. Proc Natl Acad Sci U S A. 2011;108:751–6.CrossRefPubMedPubMedCentral
97.
Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al. Oral fingolimod (fty720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124–40.CrossRefPubMed
98.
Vogelgesang A, Grunwald U, Langner S, Jack R, Broker BM, Kessler C, et al. Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke. 2008;39:237–41.CrossRefPubMed
99.
Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke. 2007;38:770–3.CrossRefPubMed
Metadata
Title
Sphingosine-1-Phosphate Signaling in Endothelial Disorders
Author
Teresa Sanchez
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 6/2016
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-016-0586-1

Other articles of this Issue 6/2016

Current Atherosclerosis Reports 6/2016 Go to the issue

Vascular Biology (J. Hamilton, Section Editor)

Macrophages in Vascular Inflammation: Origins and Functions

Vascular Biology (J. Hamilton, Section Editor)

Plaque Rupture and Thrombosis: the Value of the Atherosclerotic Rabbit Model in Defining the Mechanism

Vascular Biology (J. Hamilton, Section Editor)

PET Imaging of Atherosclerotic Disease: Advancing Plaque Assessment from Anatomy to Pathophysiology

Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Antiplatelet Management for Coronary Heart Disease: Advances and Challenges

Vascular Biology (J. Hamilton, Section Editor)

Dynamic Contrast-Enhanced MRI to Study Atherosclerotic Plaque Microvasculature

Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Myocardial Viability and Revascularization: Current Understanding and Future Directions

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits